Next-gen weight-loss drugs: the amylin shots to watch

Semaglutide and tirzepatide rewrote obesity treatment by imitating GLP-1, a gut hormone that tells the brain to stop eating. The catch is tolerability. Roughly four in 10 patients who begin these weekly injections stop within the first year, worn down by nausea, vomiting, and abdominal cramps.